Posted by Michael Wonder on 10 Aug 2020
Gilead submits new drug application to U.S. Food and Drug Administration for Veklury (remdesivir) for the treatment of COVID-19
10 August 2020 - Veklury is currently available in the U.S. for the treatment of severe COVID-19 under an Emergency Use Authorisation.
Gilead Sciences announced today that it has submitted a new drug application to the U.S. FDA for Veklury (remdesivir), an investigational antiviral for the treatment of patients with COVID-19. Veklury is currently available in the U.S. under an Emergency Use Authorisation for the treatment of hospitalised patients with severe COVID-19.
The filing is the final tier of the rolling NDA submission that was initiated on 8 April 2020.
